![System.Func`1[System.String]](/siteassets/images/z-mckesson-logosicons/specialty-practice-solutions.png)
Biosimilars for Specialty Practices
Biosimilars are a rapidly growing treatment option for physicians treating advanced diseases, with more than 20 unique biosimilars expected to enter the U.S. healthcare market over the next decade. Learn more about these safe and effective treatment options.
Uncovering the Path to Successful Biosimilar Adoption for Your Specialty Practice
If your specialty practice is preparing to adopt biosimilars, McKesson can help. We clear the path by creating a roadmap for success. Our advisors and resources can help you navigate every step of the biosimilar journey, from patient education to developing training programs. McKesson also supports specialty practices like yours with communicating the facts clearly, implementing efficient workflows and driving operational excellence so you can focus on what matters most - caring for your patients. Watch this video to learn more.
Read below for biosimilar resources at every stage: biosimilar beginners, considerations when using biosimilars, and best practices post-adoption.
New to biosimilars?
- Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from existing, FDA-approved reference biologics.
- While biosimilars are similar to their reference biological product, they are not generic equivalents.
- Biosimilars go through a rigorous FDA review process including analytical, animal and clinical studies.
Biosimilars go through an extensive FDA approval process and offer safe, effective therapeutic options for serious diseases
As more biosimilars become available in the U.S., providers, payers and patients all stand to benefit from further incorporating these safe and effective therapies throughout our healthcare ecosystem.
Rising healthcare costs, increasing drug production demands and reimbursement pressures are all putting a serious strain on our nation’s healthcare delivery system. By adopting biosimilars routinely into patient treatment decisions, we can improve overall access to critical, life-saving drugs all while reducing the costs of these expensive therapies through increased competition.
Learn more about the McKesson services available to support biosimilar and other practice needs by visiting our Solutions for Specialty Practices page.
Considering adopting biosimilars in your treatment regimens?
Biosimilars currently available through McKesson include:
|
Biosimilar |
Biologic |
HCPCS |
Patient |
Full |
|---|---|---|---|---|
|
Tofidence |
Actemra |
|
FDA Drug Info |
|
|
Tyenne |
Actemra |
|
FDA Drug Info |
|
|
Alymsys |
Avastin |
Q5126 |
FDA Drug Info |
|
|
Mvasi |
Avastin |
Q5107 |
FDA Drug Info |
|
|
Vegzelma |
Avastin |
Q5129 |
FDA Drug Info |
|
|
Zirabev |
Avastin |
Q5118 |
FDA Drug Info |
|
|
Retacrit |
Epogen/Procrit |
Q5105 |
FDA Drug Info |
|
|
Herzuma |
Herceptin |
Q5113 |
FDA Drug Info |
|
|
Kanjinti |
Herceptin |
Q5117 |
FDA Drug Info |
|
|
Ogivri |
Herceptin |
Q5114 |
FDA Drug Info |
|
|
Ontruzant |
Herceptin |
Q5112 |
FDA Drug Info |
|
|
Trazimera |
Herceptin |
Q5116 |
FDA Drug Info |
|
|
Amjevita |
Humira |
|
FDA Drug Info |
|
|
Byooviz |
Lucentis |
Q5124 |
FDA Drug Info |
|
|
Cimerli |
Lucentis |
Q5128 |
FDA Drug Info |
|
|
Fulphila |
Neulasta |
Q5108 |
FDA Drug Info |
|
|
Fylnetra |
Neulasta |
Q5130 |
FDA Drug Info |
|
|
Nyvepria |
Neulasta |
Q5122 |
FDA Drug Info |
|
|
Stimufend |
Neulasta |
Q5127 |
FDA Drug Info |
|
|
Udenyca |
Neulasta |
Q5111 |
FDA Drug Info |
|
|
Ziextenzo |
Neulasta |
Q5120 |
FDA Drug Info |
|
|
Nivestym |
Neupogen |
Q5110 |
FDA Drug Info |
|
|
Releuko |
Neupogen |
Q5125 |
FDA Drug Info |
|
|
Zarxio |
Neupogen |
Q5101 |
FDA Drug Info |
|
|
Avsola |
Remicade |
Q5121 |
Amgen SupportPlus |
FDA Drug Info |
|
Inflectra |
Remicade |
Q5103 |
FDA Drug Info |
|
|
Renflexis |
Remicade |
Q5104 |
FDA Drug Info |
|
|
Riabni |
Rituxan |
Q5123 |
FDA Drug Info |
|
|
Ruxience |
Rituxan |
Q5119 |
FDA Drug Info |
|
|
Truxima |
Rituxan |
Q5115 |
FDA Drug Info |
Four Reasons to Consider Adopting Biosimilars for Your Treatment Regimens
As biosimilars continue to gain traction in the medical community, here are four good reasons to incorporate them into your treatment plans:
Substantial Cost Savings on Expensive Therapies
FDA-Approved, Safe and Effective Treatments
Support from FDA and Other Leading Medical Advisory Organizations
Biosimilar 101 Resources
Highlights
Biosimilar Master Class
Dr. Robert Rifkin and our team of expert clinical specialists and business advisors help you understand biosimilars from the U.S. Food and Drug Administration (FDA) perspective.
Highlights
A Guide to Navigating Biosimilars
From 2017 to 2020, McKesson helped specialty providers save more than $386 million dollars through biosimilar adoption.
ADDITIONAL READING
Biosimilar Perspectives from McKesson Experts
Navigating Biosimilar Reimbursement: Key Challenges and Steps to Success
McKesson’s experts address the most important clinical, operational, and economical obstacles to overcome on the path to reimbursement.
Three Biosimilar Barriers in Community Clinic
An in depth look at the primary concerns of physicians when implementing biosimilars in their oncology and rheumatology practices.
From Clinical Use to Reimbursement
Dr. Robert Rifkin, medical director of biosimilars for McKesson, gives an update on biosimilar education and reimbursement.
Perfect Storm for Biosimilar Marketing
Dr. Robert Rifkin discusses the "perfect storm" for biosimilar marketing in a recent OncLive article.
Biosimilars: A Recent Review of Clinical Outcomes
A review of 14,000 individuals transitioned from a reference biologic medication to a biosimilar examines patient safety and treatment efficacy.
Biosimilar Resources and Education
Resource
Biosimilar Master Class
Dr. Robert Rifkin and our team of expert clinical specialists and business advisors help you understand biosimilars from the U.S. Food and Drug Administration (FDA) perspective.
Resource
A Guide to Navigating Biosimilars
From 2017 to 2020, McKesson helped specialty providers save more than $386 million dollars through biosimilar adoption.
EDUCATION
CMS Medicare Guidance on Biosimilar Reimbursement
Stay up to date on new Medicare HCPCS codes and reimbursement guidance on biosimilars.
EDUCATION
FDA Biosimilar Resources for Your Practice
Visit the FDA biosimilar website for provider and patient-facing biosimilar resources. Topics include the latest FDA approvals, biosimilar 101 education, regulatory review and approval, interchangeability guidance and more.
Resource
Barriers to Biosimilar Adoption
Overcoming physician barriers to adoption in clinics.
VIEWPOINT
Biosimilar Endorsements From Major Medical Advisory Organizations
Read about the benefits of biosimilar growth from major Oncology and Rheumatology advisory bodies.
Contact McKesson Specialty Practice Solutions
Specialty care requires a special approach—one that’s done your way. Let’s connect, and explore how McKesson can optimize your specialty practice.
Customer Support
-
Call McKesson Customer Care for oncology practices.
-
Call McKesson Customer Care for other specialty practices.
Sales Contacts
-
Oncology, rheumatology, gastroenterology, ophthalmology, neurology, and other specialty practices:
-
Practices in The US Oncology Network:
Customer Login